Develop Best Practices for a Shifting Landscape

The CUSMA trade talks and the National Pharmacare program that is fragmented and seemingly stalled have introduced considerable uncertainty into the marketplace and the path forward.  Gain a better understanding of the impact on manufacturers and how private insurers may respond.  Take away ideas to:

• Assess the impact this uncertainty has on allocating coverage of some medications between national pharmacare where it exists and private plans
• Determine what impact Trump’s MFN call could have on manufacturer’s pricing decisions and the approach private insurers may take in response
• How private payers can improve plan sustainability
• Understand what drugs and therapies private payers will continue to cover and their listing criteria to enhance your submissions

Develop a solid submission strategy that addresses private payer challenges.